Zeidner, J. F., Yuda, J., Watts, J. M., Levis, M. J., Erba, H. P., Fukushima, K., … Daver, N. (2024). Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia. In Blood (Vol. 144, pp. 213–213). American Society of Hematology. https://doi.org/10.1182/blood-2024-194827

Zeidner, Joshua F., Junichiro Yuda, Justin M. Watts, Mark J. Levis, Harry P. Erba, Kentaro Fukushima, Takahiro Shima, et al. “Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia.” In Blood, 144:213–213. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-194827.

Zeidner JF, Yuda J, Watts JM, Levis MJ, Erba HP, Fukushima K, et al. Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia. In: Blood. American Society of Hematology; 2024. p. 213–213.

Zeidner, Joshua F., et al. “Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 213–213. Crossref, doi:10.1182/blood-2024-194827.

Zeidner JF, Yuda J, Watts JM, Levis MJ, Erba HP, Fukushima K, Shima T, Palmisiano ND, Wang ES, Borate U, Brandwein J, Papayannidis C, Montesinos P, Keiffer G, Miyazaki Y, Hosono N, Ikezoe T, Ogawa Y, Pardee TS, Strickland SA, Onodera K, Wu S-J, Ooi MG, Raffoux E, Vives S, Eghtedar A, Cai H, Allred C, Xu B, Robson P, Watanabe A, Hitron M, Shah J, Kantarjian HM, Daver N. Phase 1 Results: First-in-Human Phase 1/2 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Patients with Relapsed or Refractory Acute Leukemia. Blood. American Society of Hematology; 2024. p. 213–213.